Advancing neurological therapies with Dr Bruce Leuchter
Drug Target Review
FEBRUARY 1, 2024
Part of the challenge is that patients present with very different kinds of clinical phenotypes, meaning the populations are heterogeneous. This can present challenges when attempting to recruit an enriched patient population for clinical trials. This has been a hot button issue in neuroscience for as long as I can remember.
Let's personalize your content